These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34920925)

  • 1. Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021.
    Trapani D; Curigliano G
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S54-S57. PubMed ID: 34920925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy.
    Jeong JH; Kim SB
    Breast; 2022 Dec; 66():199-203. PubMed ID: 36327625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Zardavas D
    Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis.
    Püsküllüoğlu M; Rudzińska A; Pacholczak-Madej R
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188991. PubMed ID: 37758021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
    Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
    Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
    Grinda T; Rassy E; Pistilli B
    Curr Treat Options Oncol; 2023 May; 24(5):442-465. PubMed ID: 36966267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer.
    Bhardwaj PV; Abdou YG
    Oncologist; 2023 Oct; 28(10):832-844. PubMed ID: 37597245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
    Pondé N; Aftimos P; Piccart M
    Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple negative breast cancer: any closer to cracking the code?
    Peddi PF
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
    Corti C; Antonarelli G; Valenza C; Nicolò E; Rugo H; Cortés J; Harbeck N; Carey LA; Criscitiello C; Curigliano G
    Eur J Cancer; 2022 Aug; 171():25-42. PubMed ID: 35696887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
    Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
    J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rise of Antibody-Drug Conjugates: The Present and Future.
    Shastry M; Gupta A; Chandarlapaty S; Young M; Powles T; Hamilton E
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390094. PubMed ID: 37229614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.
    Montero JC; Calvo-Jiménez E; Del Carmen S; Abad M; Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):106. PubMed ID: 35317825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.